• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Events
  • Education
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
    • Patient perspective
  • PIPcast
  • Jobs
  • Business Directory

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

GSK discontinue Haleraid® device

10th July 2020 by PIP editor Leave a Comment

 

GSK has taken the decision to discontinue the manufacture of the Haleraid® inhaler device.

 

Haleraid® is a device to place over pressurised metred dose inhalers to aid when the strength in the hands of a patient is compromised.

 

Haleraid® has been designed specifically for use with Flixotide®, Seretide®, Serevent®, and Ventolin® inhalers.

 

The device is currently not allowed on NHS prescriptions.

 

Consultant Pharmacist Anna Murphy commented on the decision on Twitter:

 

“I can’t believe GSK has made the decision to discontinue the Haleraid® 200 and 120 dose. Such an important support tool for patients using MDIs who are unable to press the canister due to dexterity issues. Why not add to part IX drug tariff and increase their availability?”

 

“Why am I not surprised by the corporate response but this is very much a patient safety issue. If readily available it would benefit so many more of our elderly frail patients and improve patient care. Reminds me of GSK and the Volumatic …. time to lobby for our patients!”

 

Speaking to PIP, GSK commented:

 

“Prior to 2020, only three countries outside of the UK continued to have a supply of Haleraid®, with the product discontinued in Ireland since 2014.

 

“Following a considered review with our manufacturing partner, a variety of factors including regulatory changes, third party contracting and decreasing global demand have contributed to this global decision to discontinue Haleraid® 200 dose and Haleraid 120 dose.

 

“We formally notified the Medicines and Healthcare products Regulatory Authority (MHRA) of our decision to remove registration for the product in the UK in May 2020.

 

“We regret that this global decision, which was not taken lightly, means that UK patients will not have access to Haleraid®.  It is important that we listen to the concerns that have been raised and following discussions with interested healthcare professionals and external organisation we will work in partnership towards a sustainable solution for patients in the UK going forward.

 

“In the interim patients can continue to use Haleraid® devices they have as normal. For any alternatives, patients should discuss these with their doctor or other healthcare professional.”

 

Catch up with the conversation here.

 

 

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Related

Next article  £5million invested in community pharmacy delivery service

Filed Under: News Tagged With: Inhaler

Register for our upcoming webinar and live Q&A

About PIP editor

Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.

Reader Interactions

Begin the discussion right here Cancel reply

Primary Sidebar

Categories

Follow Us

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter

PIP business directory

Letters to the editor

Letters to the editor

Is there a pragmatic way through the provisional registration problem?

It is difficult to know how to ask a patient if they can read

Pharmacies should be allowed to supply rapid antibody tests

Pharmacists are disillusioned, disenfranchised and marginalised

More letters to the editor here...

Blogs

💊 PIP live pharmacy blog

Winter stresses must not ‘destabilise’ general practice

What is it like to depend on medicine to treat endometriosis?

Opinion

Why is pharmacy not integral to government mass vaccination plans?

Pharmacy Covid-19 vaccination involvement is a ‘no-brainer’

The great patient medication returns debacle

CPD Challenges

💊 CPD Challenge: How well do you understand pulmonary embolisms?

💊 CPD Challenge: Prescribing and dispensing clozapine

💊 CPD Challenge: Oral anticoagulants – Dabigatran

More CPD challenges here...

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.